Class Action Lawsuit Against Applied Therapeutics, Inc.
NEW YORK, Dec. 19, 2024 – Levi & Korsinsky, LLP has informed investors about a class action securities lawsuit involving Applied Therapeutics, Inc. This action centers around claims of securities fraud that impacted investors between specific dates in early December 2024.
Understanding the Class Definition
The class action aims to recover losses for those who suffered due to alleged fraudulent activities involving the Company's securities. Investors are encouraged to come forward and gather more information about their potential claims.
Recent Developments Affecting APLT Shares
Recently, Applied Therapeutics announced it received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application (NDA) for their leading drug candidate, govorestat. This critical announcement spurred a significant decline in the Company’s stock price, which dropped from $10.21 to as low as $1.29 within a short timeframe.
Decline in Stock Prices Explained
On November 27, 2024, the stock price fell drastically following the CRL announcement. Initial market reactions saw shares decline to $8.57. Subsequent updates regarding a warning letter from the FDA highlighted issues in clinical trials, contributing to further stock price drops, culminating in a staggering total decline exceeding 80%.
How to Take Action
Investors who believe they have experienced losses with Applied Therapeutics are advised to act promptly. To become a lead plaintiff in the case, a request must be made by the approaching deadline in February. Participants are not obligated to take on the role of lead plaintiff to share in any potential recovery.
No Financial Risk to Participants
Joining this class action comes at no financial risk to class members; there are no out-of-pocket costs or fees. The law firm assures that there is no obligation for investors to participate.
Why Choose Levi & Korsinsky?
Levi & Korsinsky has built a strong reputation in the field of securities litigation over the past two decades. The firm has successfully secured compensation for numerous investors facing similar issues and benefits from an experienced team skilled in pursuing high-stakes legal matters. For seven consecutive years, it has ranked among the top securities litigation firms nationwide.
Contact Information
For those interested in more details, reach out to the team at Levi & Korsinsky, LLP:
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
Email: jlevi@levikorsinsky.com
Phone: (212) 363-7500
Fax: (212) 363-7171
Website: www.zlk.com
Frequently Asked Questions
What is the lawsuit about?
The lawsuit addresses securities fraud claims impacting investors in Applied Therapeutics.
When is the deadline to join the class action?
The deadline to request participation as a lead plaintiff is February 18, 2025.
Are there any costs to participate in the lawsuit?
No, there are no costs or obligations for investors to join the class action.
What caused the decline in APLT stock price?
The decline was primarily due to an FDA Complete Response Letter and subsequent warning letter concerning clinical trial deficiencies.
How can I contact Levi & Korsinsky for more information?
You can reach them at (212) 363-7500 or via email at jlevi@levikorsinsky.com.
